

**CURRENT STATUS OF CLAIMS WITH CLAIM AMENDMENTS**

1-7. **Canceled.**

8. **(Presently amended)** [The method of claim 1, wherein said VEGFR-3 inhibitor is a VEGFR-3] **A method of extending corneal graft survival following corneal transplantation in a patient, comprising:**

**administering to said patient an effective amount of a pharmaceutical composition comprising a vascular endothelial growth factor receptor-3 (VEGFR-3)** kinase inhibitor,

**whereby lymphangiogenesis is suppressed in the cornea of said patient.**

9. **(Original)** The method of claim 8, wherein said VEGFR-3 kinase inhibitor binds the VEGFR-3 catalytic domain.

10. **(Original)** The method of claim 9, wherein said VEGFR-3 kinase inhibitor is an ATP analog.

11-14. **Canceled.**

15. **(Presently amended)** The method of claim 8 [1], wherein said VEGFR-3 inhibitor down-regulates VEGFR-3 expression.

16-25. **Canceled.**

26. **(Presently amended)** The method of claim 8 [1], further comprising administering to said patient an anti-angiogenic agent.

27. **(Presently amended)** The method of claim 8 [1] or claim 26, further comprising administering to said patient an immunosuppressive agent.

28. **(Presently amended)** The method of claim 8 [1], wherein said pharmaceutical composition is administered prior to corneal transplantation.

29. **(Presently amended)** The method of claim 8 [1], wherein said pharmaceutical composition is administered subsequent to corneal transplantation.

30. **(Presently amended)** The method of claim 8 [1], comprising administering to said patient an effective amount of a pharmaceutical composition comprising a VEGFR-3 inhibitor two or more times.

31. (Original) The method of claim 30, comprising repeated administration over a period of at least one month.

32. (Original) The method of claim 30, comprising repeated administration over a period of at least six months.

33. (Original) The method of claim 30, comprising:

(a) administering to said patient prior to corneal transplantation a pharmaceutical composition comprising a VEGFR-3 inhibitor; and

(b) administering to said patient subsequent to corneal transplantation a pharmaceutical composition comprising a VEGFR-3 inhibitor,

whereby lymphangiogenesis is suppressed in the cornea of said patient.

34. **(Presently amended)** The method of claim 8 [1], comprising systemic administration of said pharmaceutical composition.

35. **(Presently amended)** The method of claim 8 [1], comprising local administration of said pharmaceutical composition.

36. (Original) The method of claim 35, comprising topical administration of said pharmaceutical composition.

Inventor: Gerald W. DeVries  
Serial No.: 10/081,126  
Filed: February 22, 2002  
Page 4

37. (Original) The method of claim 35, comprising local injection of said pharmaceutical composition.

38. (Original) The method of claim 35, said pharmaceutical composition released from an intraocular or periocular implant.